India


HOLD (previously REDUCE)

Consensus ratings*: B	uy 5	Hold 2	Sell 9
Current price:			Rs447
Target price:			Rs455
Previous target:			Rs307
Up/downside:			1.8%
InCred Research / Conse	nsus	:	14.3%
Reuters:			
Bloomberg:		LAU	JRUS IN
Market cap:		US	\$2,868m
		Rs2	41,166m
Average daily turnover:		U	S\$14.3m
		Rs	1200.9m
Current shares o/s:			538.7m
Free float:			72.8%
*Source: Bloomberg			

Key changes in this note

> Upgrade our rating to HOLD from REDUCE.

- Raise our target price to Rs455 from Rs307.
- Revise our FY25F/26F EPS estimates by +3%/-1%.



	 	()
Major shareholders	0	6 held
Promoters		27.2
Capital group		9.4
Amansa		4.1

Research Analyst(s)



Praful BOHRA T (91) 22 4161 1552 E praful.bohra@incredresearch.com Yogesh SONI T (91) 22 4161 1566 E yogesh.soni@incredresearch.com

Laurus Labs

Performance close to the bottom?

- An in-line 2Q performance based on our low expectations; a sharp miss vs. consensus. 4QFY25F should reflect a meaningful shift in earnings trajectory.
- For the last two quarters, gross margin broadly sustained at around the 55% level. Revenue pick-up can thus drive a meaningful margin upside.
- Our FY25F/26F EPS estimates are nearly unchanged. Upgrade our rating on the stock to HOLD as we feel we are getting closer to earnings reversal cycle.

2QFY25 performance in line with expectations

Laurus Labs' 2QFY25 performance aligned with our expectations but fell significantly short of the Bloomberg or BB consensus expectations (margin 100bp lower than the BB consensus estimate). For the last two quarters, the gross margin broadly sustained around the 55% level while the lower EBITDA margin was largely on account of lower asset utilization and negative operating leverage. The company has invested around Rs26bn over FY22-24 and will invest another Rs18-20bn in FY25F/26F. Further, Laurus Labs has invested around Rs4.7bn across technologies (gene therapy/cell therapy/precision fermentation, etc.) – these initiatives are yet to contribute meaningfully and have been dragging the margin. We expect the margin trajectory to reverse from here on, with some ramp-up in CDMO supplies for the animal health contracts (typically higher gross margin contracts) from 3QFY25F and a meaningful ramp-up from 4QFY25F. This should positively impact on the EBITDA margin too, and we expect a 4QFY25F exit run-rate of 25% (vs. 14.5% in 1HFY25).

Lower API sales but CDMO revenue picks up well

2QFY25 revenue was hit by lower API sales (lower demand in oncology APIs, temporary plant shutdown and continued pricing pressure), although the CDMO business was strong (up 33% YoY). FDF sales were flat YoY. Margin stood at 14.6%, impacted by negative operating leverage. Laurus Labs gave guidance of a 20% margin in FY25F, implying ~25% run-rate for 2HFY25F – we bake in 18.5% margin in FY25F, with an exit run-rate of 25% in 4QFY25F.

Stock price largely underperforms the broader market

Our negative stance on Laurus Labs over the past five-to-six quarters was driven by the anticipated margin pressure & potential earnings cuts. While the stock price has held steady in absolute terms, it has underperformed the BSE Healthcare Index by nearly 30% over the past one year. We now see an earnings recovery on the horizon, with margins expected to rebound to ~25% by 4QFY25F. Our FY26F margin forecast of 22.5% (+400bp YoY) reflects this shift.

We upgrade the stock's rating to HOLD from REDUCE

Our FY25F/26F earnings estimates remain largely unchanged. With earnings recovery imminent, we upgrade the stock's rating to HOLD (from REDUCE), valuing it at 47x FY26F EPS, leading to a higher target price of Rs455 (Rs307 earlier). Downside risks: Slower-than-expected margin improvement. Upside risk: Faster recovery in margin.

Financial Summary	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
Revenue (Rsm)	49,356	60,406	50,408	53,310	61,517
Operating EBITDA (Rsm)	14,224	15,922	7,775	9,881	13,847
Net Profit (Rsm)	8,275	7,901	1,623	2,628	5,244
Core EPS (Rs)	15.4	14.7	3.0	4.9	9.7
Core EPS Growth	(15.9%)	(4.5%)	(79.5%)	61.9%	99.6%
FD Core P/E (x)	29.12	30.50	148.49	91.70	45.95
DPS (Rs)	1.6	4.0	2.0	2.0	2.0
Dividend Yield	0.36%	0.89%	0.45%	0.45%	0.45%
EV/EBITDA (x)	18.09	16.32	33.88	26.64	19.14
P/FCFE (x)	26.25	24.64	36.77	16.74	22.84
Net Gearing	49.3%	47.5%	57.5%	55.2%	54.1%
P/BV (x)	7.19	5.97	5.86	5.64	5.13
ROE	27.8%	21.4%	4.0%	6.3%	11.7%
% Change In Core EPS Estimates				2.83%	(0.66%)
InCred Research/Consensus EPS (x)					

SOURCE: INCRED RESEARCH, COMPANY REPORTS

InCred Equities

(Rsm)	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	Y-o-Y (%)	Q-o-Q (%)
Revenue	15,759	15,448	13,809	11,818	12,245	11,949	14,397	11,949	12,237	0%	2%
Consumption of raw materials	7,074	7,194	6,946	5,839	5,811	5,454	7,220	5,369	5,483	-6%	2%
as % of sales	44.9%	46.6%	50.3%	49.4%	47.5%	45.6%	50.2%	44.9%	44.8%		
Employee costs	1,470	1,474	1,343	1,599	1,639	1,550	1,611	1,740	1,787	9%	3%
as % of sales	9.3%	9.5%	9.7%	13.5%	13.4%	13.0%	11.2%	14.6%	14.6%		
R&D costs	490	550	580	470	580	670	690	640	670	16%	5%
as % of sales	3.1%	3.6%	4.2%	4.0%	4.7%	5.6%	4.8%	5.4%	5.5%		
Other expenditure	2236	2195	2085	2242	2336	2461	2461	2489	2514	8%	1%
as % of sales	14.2%	14.2%	15.1%	19.0%	19.1%	20.6%	17.1%	20.8%	20.5%		
EBITDA	4,489	4,036	2,855	1,667	1,879	1,814	2,415	1,712	1,783	-5%	4%
Margins (%)	28.5%	26.1%	20.7%	14.1%	15.3%	15.2%	16.8%	14.3%	14.6%		
Depreciation	818	844	870	906	934	984	1,023	1,061	1,075		
Other income	11	14	17	36	18	24	185	25	46		
Interest	401	427	531	392	424	508	505	492	526		
PBT	3,281	2,779	1,471	406	539	346	1,073	185	228	-58%	24%
Total tax	943	748	399	122	146	95	320	63	51		
Tax Rate (%)	28.7%	26.9%	27.1%	30.0%	27.0%	27.3%	29.8%	33.9%	22.3%		
PAT before MI	2,338	2,031	1,072	284	393	252	753	122	177	-55%	45%
Minority interest (MI)	-10	0	-43	-36	-24	-18	-3	5	22		
Adj. PAT before extraordinary items	2,328	2,030	1,030	248	370	233	750	127	200	-46%	57%
Extraordinary expenses	0	0	0	0	0	0	0	0	0		
Reported PAT	2,328	2,030	1,030	248	370	233	750	127	200	-46%	57%
No. of shares	537.4	538.7	538.7	538.7	538.7	540.0	540.0	538.7	538.7		
EPS	4.3	3.8	1.9	0.5	0.7	0.4	1.4	0.2	0.4		

Figure 2: Margin profile											
(in %)	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	Y-o-Y (bp)	Q-o-Q (bp)
Gross	55%	53%	50%	51%	53%	54%	50%	55%	55%	265	12
EBITDA	28%	26%	21%	14%	15%	15%	17%	14%	15%	-77	25
Adj.PAT	15%	13%	7%	2%	3%	2%	5%	1%	2%	-139	57
Effective tax rate	29%	27%	27%	30%	27%	27%	30%	34%	22%	-472	-1154
								SOURCE: INCR	RED RESEAR	CH, COMPAN	NY REPORTS

Figure 3: Revenue mix											
(Rsm)	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	Y-o-Y (%)	Q-o-Q (%)
Antiviral API	4,017	3,729	3,499	4,060	3,711	3,501	4,098	3,984	3,676	-1%	-8%
% total revenue	25.5%	24.1%	25.3%	34.4%	30.3%	29.3%	28.5%	33.3%	30.0%		
Oncology API	545	758	1,285	537	1,195	861	1,490	1,195	501	-58%	-58%
% total revenue	3.5%	4.9%	9.3%	4.5%	9.8%	7.2%	10.3%	10.0%	4.1%		
Other API	2,238	1,833	2,356	1,373	1,384	1,378	1,863	1,461	1,393	1%	-5%
% total revenue	14.2%	11.9%	17.1%	11.6%	11.3%	11.5%	12.9%	12.2%	11.4%		
FDF	1,490	2,490	3,930	2,850	3,320	3,670	4,300	2,740	3,280	-1%	20%
% total revenue	9.5%	16.1%	28.5%	24.1%	27.1%	30.7%	29.9%	22.9%	26.8%		
Synthesis	7,200	6,420	2,280	2,500	2,240	2,120	2,360	2,140	2,990	33%	40%
% total revenue	45.7%	41.6%	16.5%	21.2%	18.3%	17.7%	16.4%	17.9%	24.4%		
Bio-ingredients / other	270	220	460	500	390	420	290	430	400	3%	-7%
% total revenue	1.7%	1.4%	3.3%	4.2%	3.2%	3.5%	2.0%	3.6%	3.3%		
Total Revenue	15,759	15,448	13,809	11,818	12,245	11,950	14,400	11,949	12,237	0%	2%
							S	OURCE: INCR	ED RESEAR	CH, COMPAN	Y REPORTS

Figure 4: Actuals vs estimates					
	Actuals	Incred Est.	Variance (%)	Bloomberg Est.	Variance (%)
Revenue (Rs. m.)	12,237	12,515	-2.2	12,822	-4.6
EBITDA (Rs. m)	1,783	1,758	1.4	2,001	-10.9
Margin (%)	14.6	14.0		15.6	
PAT (Rs. m)	200	178	11.8	325	-38.6
			SOUF	RCE: INCRED RESEARCH, C	COMPANY REPORTS

Figure 5: Our revised earnings es	timates					
		FY25F			FY26F	
	Old	New	% change	Old	New	% change
Revenue (Rsm)	54,465	53,310	(2.1)	62,521	61,517	(1.6)
EBITDA (Rsm)	9,627	9,881	2.6	13,484	13,847	2.7
Margin (%)	17.7	18.5		21.6	22.5	
PAT (Rsm)	2,555	2,628	2.8	5,279	5,244	(0.7)
EPS (Rs)	4.7	4.8		9.7	9.6	
				SOURCE: INCR	ED RESEARCH, COM	MPANY REPORTS


InCred Equities



InCred Equities

Pharmaceuticals | India Laurus Labs | October 25, 2024

BY THE NUMBERS



Profit & Loss					
(Rs mn)	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
Total Net Revenues	49,356	60,406	50,408	53,310	61,517
Gross Profit	27,418	32,662	26,084	29,640	35,065
Operating EBITDA	14,224	15,922	7,775	9,881	13,847
Depreciation And Amortisation	(2,515)	(3,241)	(3,846)	(4,300)	(4,800)
Operating EBIT	11,709	12,681	3,929	5,581	9,047
Financial Income/(Expense)	(1,024)	(1,652)	(1,829)	(2,160)	(2,100)
Pretax Income/(Loss) from Assoc.					
Non-Operating Income/(Expense)	153	60	263	131	100
Profit Before Tax (pre-El)	10,839	11,089	2,364	3,552	7,047
Exceptional Items					
Pre-tax Profit	10,839	11,089	2,364	3,552	7,047
Taxation	(2,515)	(3,123)	(682)	(995)	(1,903)
Exceptional Income - post-tax					
Profit After Tax	8,324	7,966	1,682	2,558	5,144
Minority Interests	(49)	(65)	(59)	70	100
Preferred Dividends					
FX Gain/(Loss) - post tax					
Other Adjustments - post-tax					
Net Profit	8,275	7,901	1,623	2,628	5,244
Recurring Net Profit	8,275	7,901	1,623	2,628	5,244
Fully Diluted Recurring Net Profit	8,275	7,901	1,623	2,628	5,244

Cash Flow					
(Rs mn)	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
EBITDA	14,224	15,922	7,775	9,881	13,847
Cash Flow from Invt. & Assoc.					
Change In Working Capital	(3,416)	(3,153)	(290)	2,239	(2,768)
(Incr)/Decr in Total Provisions					
Other Non-Cash (Income)/Expense					
Other Operating Cashflow	(1,697)	(2,830)	(828)	(925)	(1,803)
Net Interest (Paid)/Received	(1,024)	(1,652)	(1,829)	(2,160)	(2,100)
Tax Paid	(826)	(1,239)	738	1,104	197
Cashflow From Operations	9,111	9,939	6,657	11,195	9,276
Capex	(8,767)	(9,875)	(6,760)	(8,000)	(8,000)
Disposals Of FAs/subsidiaries					
Acq. Of Subsidiaries/investments	(276)	(223)			
Other Investing Cashflow					
Cash Flow From Investing	68	(159)	(103)	3,195	1,276
Debt Raised/(repaid)					
Proceeds From Issue Of Shares	43	74	26		
Shares Repurchased					
Dividends Paid	(859)	(1,404)	(862)	(1,080)	(1,083)
Preferred Dividends					
Other Financing Cashflow	1,022	1,207	1,871	(2,331)	(992)
Cash Flow From Financing	207	(122)	1,035	(3,411)	(2,075)
Total Cash Generated	274	(281)	932	(216)	(798)
Free Cashflow To Equity	9,179	9,780	6,554	14,391	10,552
Free Cashflow To Firm	10,203	11,432	8,383	16,551	12,652

SOURCE: INCRED RESEARCH, COMPANY REPORTS

BY THE NUMBERS...cont'd

(Rs mn)	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
Total Cash And Equivalents	766	485	1,417	1,201	402
Total Debtors	13,542	15,804	16,629	15,993	17,225
Inventories	17,603	16,848	18,454	18,659	19,686
Total Other Current Assets	1,536	1,480	1,850	1,866	2,153
Total Current Assets	33,446	34,617	38,350	37,718	39,466
Fixed Assets	32,086	37,002	40,475	44,175	47,375
Total Investments	308	499	1,240	1,240	1,240
Intangible Assets	2,571	2,592	2,653	2,653	2,653
Total Other Non-Current Assets	1,269	1,894	1,152	1,152	1,152
Total Non-current Assets	36,234	41,987	45,521	49,221	52,421
Short-term Debt	11,357	12,106	17,088	17,088	17,088
Current Portion of Long-Term Debt					
Total Creditors	8,764	7,107	10,512	10,122	9,307
Other Current Liabilities	6,690	5,111	3,522	5,736	6,329
Total Current Liabilities	26,810	24,323	31,123	32,946	32,724
Total Long-term Debt	5,963	7,614	7,982	7,680	8,688
Hybrid Debt - Debt Component					
Total Other Non-Current Liabilities	3,316	4,181	3,610	3,610	3,610
Total Non-current Liabilities	9,280	11,795	11,592	11,289	12,297
Total Provisions					
Total Liabilities	36,090	36,117	42,715	44,235	45,021
Shareholders Equity	33,512	40,375	41,110	42,727	46,989
Minority Interests	79	111	46	(24)	(124)
Total Equity	33,591	40,487	41,156	42,704	46,865
Kee Define					
Key Ratios					
	Mar-22A	Mar-23A	Mar-24A	Mar-25F	Mar-26F
Revenue Growth	2.5%	22.4%	(16.6%)	5.8%	15.4%
Operating EBITDA Growth	(8.3%)	11.9%	(51.2%)	27.1%	40.1%
Operating EBITDA Margin	28.8%	26.4%	15.4%	18.5%	22.5%
Net Cash Per Share (Rs)	(30.73)	(35.71)	(43.91)	(43.75)	(47.10)
BVPS (Rs)	62.21	74.95	76.31	79.32	87.23
Gross Interest Cover	11.44	7.68	2.15	2.58	4.31
Effective Tax Rate	23.2%	28.2%	28.8%	28.0%	27.0%
Net Dividend Payout Ratio					
Accounts Receivables Days	98.37	88.66	117.42	111.68	98.55
Inventory Days	277.50	226.63	264.87	286.15	264.54
Accounts Payables Days	170.96	104.40	132.19	159.10	134.04
ROIC (%)	16.5%	15.0%	4.4%	6.1%	9.1%
ROCE (%) Return On Average Assets	26.0%	22.8%	6.2%	8.3%	12.9%

SOURCE: INCRED RESEARCH, COMPANY REPORTS

DISCLAIMER

This report (including the views and opinions expressed therein, and the information comprised therein) has been prepared by Incred Research Services Private Ltd. (formerly known as Earnest Innovation Partners Private Limited) (hereinafter referred to as "IRSPL"). IRSPL is registered with SEBI as a Research Analyst vide Registration No. INH000011024. Pursuant to a trademark agreement, IRSPL has adopted "Incred Equities" as its trademark for use in this report.

The term "IRSPL" shall, unless the context otherwise requires, mean IRSPL and its affiliates, subsidiaries and related companies. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IRSPL and its affiliates/group companies to registration or licensing requirements within such jurisdictions.

This report is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means; or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of IRSPL.

The information contained in this report is prepared from data believed to be correct and reliable at the time of issue of this report.

IRSPL is not required to issue regular reports on the subject matter of this report at any frequency and it may cease to do so or change the periodicity of reports at any time. IRSPL is not under any obligation to update this report in the event of a material change to the information contained in this report. IRSPL has not any and will not accept any, obligation to (i) check or ensure that the contents of this report remain current, reliable or relevant; (ii) ensure that the content of this report constitutes all the information a prospective investor may require; (iii) ensure the adequacy, accuracy, completeness, reliability or fairness of any views, opinions and information, and accordingly, IRSPL and its affiliates/group companies (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

Unless otherwise specified, this report is based upon reasonable sources. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from our research. While every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of IRSPL and its affiliates/group companies to any person to buy or sell any investments.

The opinions expressed are based on information which is believed to be accurate and complete and obtained through reliable public or other nonconfidential sources at the time made (information barriers and other arrangements may be established, where necessary, to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/their coverage of company(ies) in the performance of his/their duties or the performance of his/their recommendations. In reviewing this report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request. The report is not a "prospectus" as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India. No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

IRSPL may have issued other reports (based on technical analysis, event specific, short-term views, etc.) that are inconsistent with and reach a different conclusion from the information presented in this report.

Holding of Analysts/Relatives of Analysts, IRSPL and Associates of IRSPL in the covered securities, as on the date of publishing of this report

Research Analyst or his/her relative(s) or InCred Research Services Private Limited or our associate may have any financial interest in the subject company.

Research Analyst or his/her relatives or InCred Research Services Limited or our associates may have actual or beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of the Research Report.

Research Analyst or his/her relative or InCred Research Services Private Limited or our associate entities may have any other material conflict of interest at the time of publication of the Research Report.

In the past 12 months, IRSPL or any of its associates may have:

- a) Received any compensation/other benefits from the subject company,
- b) Managed or co-managed public offering of securities for the subject company,
- c) Received compensation for investment banking or merchant banking or brokerage services from the subject company,
- d) Received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company

We or our associates may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.

Research Analyst may have served as director, officer, or employee in the subject company.

We or our research analyst may engage in market-making activity of the subject company.

Analyst declaration

- The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his
 or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and
 autonomously in an unbiased manner.
- No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report or based on any specific investment banking transaction.
- The analyst(s) has(have) not had any serious disciplinary action taken against him/her(them).
- The analyst, strategist, or economist does not have any material conflict of interest at the time of publication of this report.
- The analyst(s) has(have) received compensation based upon various factors, including quality, accuracy and value of research, overall firm performance, client feedback and competitive factors.

IRSPL and/or its affiliates and/or its Directors/employees may own or have positions in securities of the company(ies) covered in this report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities.

IRSPL and/or its affiliates and/or its Directors/employees may do and seek to do business with the company(ies) covered in this research report and may from time to time (a) buy/sell the securities covered in this report, from time to time and/or (b) act as market maker or have assumed an underwriting commitment in securities of such company(ies), and/or (c) may sell them to or buy them from customers on a principal basis and/or (d) may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) and/or (e) solicit such investment, advisory or other services from any entity mentioned in this report and/or (f) act as a lender/borrower to such company and may earn brokerage or other compensation. However, Analysts are forbidden to acquire, on their own account or hold securities (physical or uncertificated, including derivatives) of companies in respect of which they are compiling and producing financial recommendations or in the result of which they play a key part.

Recommendation	Framework
Stock Ratings	Definition:
Add	The stock's total return is expected to exceed 10% over the next 12 months.
Hold	The stock's total return is expected to be between 0% and positive 10% over the next 12 months.
Reduce	The stock's total return is expected to fall below 0% or more over the next 12 months.
	eturn of a stock is defined as the sum of the: (i) percentage difference between the target price and the current price and (ii) the forward net e stock. Stock price targets have an investment horizon of 12 months.
Sector Ratings	Definition:
Overweight	An Overweight rating means stocks in the sector have, on a market cap-weighted basis, a positive absolute recommendation.
Neutral	A Neutral rating means stocks in the sector have, on a market cap-weighted basis, a neutral absolute recommendation.
Underweight	An Underweight rating means stocks in the sector have, on a market cap-weighted basis, a negative absolute recommendation.
Country Ratings	Definition:
Overweight	An Overweight rating means investors should be positioned with an above-market weight in this country relative to benchmark.
Neutral	A Neutral rating means investors should be positioned with a neutral weight in this country relative to benchmark.
Underweight	An Underweight rating means investors should be positioned with a below-market weight in this country relative to benchmark.